Argus Investors Counsel’s Emergent Biosolutions EBS Stock Holding History

Argus Investors Counsel’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,118	Closed	-$661K	–	93
2021 Q1	$661K	Sell	7,118 -735	-9%	-$75.3K	0.27%	69
2020 Q4	$704K	Buy	7,853 +223	+3%	+$20.5K	0.31%	64
2020 Q3	$788K	Sell	7,630 -3,338	-30%	-$360K	0.33%	58
2020 Q2	$867K	Buy	10,968 +1,790	+20%	+$133K	0.42%	52
2020 Q1	$531K	Buy	+9,178	New	+$529K	0.32%	48

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Argus Investors Counsel's EBS Position: Q2 2021 in Review

Argus Investors Counsel sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 7,118 shares — an estimated $661K sold.

Argus Investors Counsel first reported a position in EBS in Q1 2020 and held it in 5 quarters. The position peaked at $867K in Q2 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

Argus Investors Counsel reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
Argus Investors Counsel sold 7,118 Emergent Biosolutions shares in Q2 2021, an estimated $661K.
Argus Investors Counsel first reported a position in Emergent Biosolutions in Q1 2020 and held it in 5 quarters.
Argus Investors Counsel's Emergent Biosolutions position peaked at $867K in Q2 2020.
290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Argus Investors Counsel's 13F filing for Q2 2021, filed 30 Jul 2021.